CFDE Data Portal | Search LRRC8C-DT

	Label	Description
	LRRC8C-DT Gene (Entity type)	ENSG00000231999 - LRRC8C divergent transcript
	GSE116810 5 V 1 SELINEXOR HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE192750 adipose overexpression Grunt Fin PNMR OE 1 v 9 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE238213 dopamine 2 v 0 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE169617 azacitidine 1 v 2 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE202434 GSE202438 talazoparib 3 v 11 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE150540 dipyridamole DPM HUVEC-C 1 v 2 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE173116 GSE173118 ML-7 4 v 0 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE172219 adenosine 2 v 1 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE146358 dopamine 5 v 2 human dn Gene Set (Entity type)	A Gene Set from LINCS

LRRC8C-DT

ENSG00000231999 - LRRC8C divergent transcript

GSE116810 5 V 1 SELINEXOR HUMAN UP

A Gene Set from LINCS

GSE192750 adipose overexpression Grunt Fin PNMR OE 1 v 9 human up

A Gene Set from LINCS

GSE238213 dopamine 2 v 0 human up

A Gene Set from LINCS

GSE169617 azacitidine 1 v 2 human up

A Gene Set from LINCS

GSE202434 GSE202438 talazoparib 3 v 11 human dn

A Gene Set from LINCS

GSE150540 dipyridamole DPM HUVEC-C 1 v 2 human up

A Gene Set from LINCS

GSE173116 GSE173118 ML-7 4 v 0 human dn

A Gene Set from LINCS

GSE172219 adenosine 2 v 1 human dn

A Gene Set from LINCS

GSE146358 dopamine 5 v 2 human dn

A Gene Set from LINCS

DISPLAY PER PAGE

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.